Skip to main content
Top
Published in: Arthritis Research & Therapy 3/2004

01-09-2004 | Oral presentation

Galectin-3 in osteoarthritis: from a protective to a destructive role

Authors: C Boileau, J Martel-Pelletier, M Guévremont, J-P Pelletier, F Poirier, P Reboul

Published in: Arthritis Research & Therapy | Special Issue 3/2004

Login to get access

Excerpt

Osteoarthritic (OA) chondrocytes are able to re-express numerous genes normally activated in the growth plate, and more particularly in the hypertrophic zone. Among several genes, we are interested in studying galectin-3 (gal-3) since we have recently demonstrated that its expression was increased in OA cartilage [1]. gal-3 is a mammalian lectin, which interacts with β-galactoside residues and is involved in numerous functions such as adhesion, splicing activity, cell cycle regulation, as well as a receptor for advanced glycation end products (AGE receptor). These functions are related to the gal-3 cellular localization. Indeed, this protein may be found in the plasma membrane, in cytoplasm and in the nucleus. …
Literature
1.
go back to reference Guévremont M, Martel-Pelletier J, Boileau C, Liu FT, Richard M, Fernandes JC, Pelletier JP, Reboul P: Human adult chondrocytes express galectin-3 to their surface: a potential substrate for collagenase-3. Annals Rheum Dis. 2004, 63: 636-643. 10.1136/ard.2003.007229.CrossRef Guévremont M, Martel-Pelletier J, Boileau C, Liu FT, Richard M, Fernandes JC, Pelletier JP, Reboul P: Human adult chondrocytes express galectin-3 to their surface: a potential substrate for collagenase-3. Annals Rheum Dis. 2004, 63: 636-643. 10.1136/ard.2003.007229.CrossRef
2.
go back to reference Colnot C, Sidhu SS, Balmain N, Poirier F: Uncoupling of chondrocyte death and vascular invasion in mouse galectin 3 null mutant bones. Dev Biol. 2001, 229: 203-214. 10.1006/dbio.2000.9933.CrossRefPubMed Colnot C, Sidhu SS, Balmain N, Poirier F: Uncoupling of chondrocyte death and vascular invasion in mouse galectin 3 null mutant bones. Dev Biol. 2001, 229: 203-214. 10.1006/dbio.2000.9933.CrossRefPubMed
3.
go back to reference Notoya K, Jovanovic DV, Reboul P, Martel-Pelletier J, Mineau F, Pelletier JP: The induction of cell death in human osteoarthritis chondrocytes by nitric oxide is related to the production of prostaglandin E2 via the induction of cyclooxygenase-2. J Immunol. 2000, 165: 3402-3410.CrossRefPubMed Notoya K, Jovanovic DV, Reboul P, Martel-Pelletier J, Mineau F, Pelletier JP: The induction of cell death in human osteoarthritis chondrocytes by nitric oxide is related to the production of prostaglandin E2 via the induction of cyclooxygenase-2. J Immunol. 2000, 165: 3402-3410.CrossRefPubMed
4.
go back to reference Ohshima S, Kuchen S, Seemayer CA, Kyburz D, Hirt A, Klinzing S, Michel BA, Gay RE, Liu FT, Gay S, Neidhart M: Galectin 3 and its binding protein in rheumatoid arthritis. Arthritis Rheum. 2003, 48: 2788-2795. 10.1002/art.11287.CrossRefPubMed Ohshima S, Kuchen S, Seemayer CA, Kyburz D, Hirt A, Klinzing S, Michel BA, Gay RE, Liu FT, Gay S, Neidhart M: Galectin 3 and its binding protein in rheumatoid arthritis. Arthritis Rheum. 2003, 48: 2788-2795. 10.1002/art.11287.CrossRefPubMed
Metadata
Title
Galectin-3 in osteoarthritis: from a protective to a destructive role
Authors
C Boileau
J Martel-Pelletier
M Guévremont
J-P Pelletier
F Poirier
P Reboul
Publication date
01-09-2004
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue Special Issue 3/2004
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar1355

Other articles of this Special Issue 3/2004

Arthritis Research & Therapy 3/2004 Go to the issue

Poster presentation

Synovial cadherin-11

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine